No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Jason Moser: Breaking up is hard to do. You're listening to Motley Fool Money. Welcome to Motley Fool Money. I'm Jason Moser, and joining me today is Motley Fool Analyst Matt Frankel. Matt, thanks for ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after ...

Hims & Hers (NYSE:HIMS) just got the cold shoulder from Novo Nordisk (NYSE:NVO). Hims had been compunding its own batches of ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) securities ...